Enhancing Molecular Insights for Improved Disease Management

Share this:
Published: 27 Oct 2017

This edition of the Genetic Technology TOE profiles about enhancing molecular insights for improved disease management. The TOE covers advanced genomic insights across pediatric healthcare, novel chimeric antigen receptor T cell (CAR-T) therapies garnering regulatory approval, new targets for Parkinson’s disease, and partnerships for the development of mRNA cancer vaccines. The corresponding clinical trials scenario for Axicabtagene Ciloleucel is depicted, along with industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Enhanced molecular insights, improved disease management, genomic insights, pediatric healthcare, Chimeric Antigen Receptor T Cell (CAR-T) therapy, regulatory approval, Parkinson’s disease, mRNA cancer vaccine.


Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..